There’s no definitive link between rebound and usage of Paxlovid, the antiviral drug that lessens the effects of COVID-19 if used near the onset of infection. Pfizer has publicized trials of the drug’s effectiveness while the Delta variant was dominant, when only 2 percent of patients reported rebound cases. With newer and more infectious variants, however, rebound cases are likely woefully undercounted, health officials say. At the same time, the exact causes of rebound remain murky.

“It’s hard to ignore the anecdotal evidence of rebounding peppered throughout social and mass media,” epidemiologist Katelyn Jetelina tells Nat Geo, as we examine rebound cases and antivirals.

Read the full story here.

Please consider getting our full digital report and magazine by subscribing here.

This email was sent to: peter.hovis@gmail.com. Please do not reply to this email as this address is not monitored.

This email contains an advertisement from:
National Geographic | 1145 17th Street, N.W. | Washington, D.C. 20036

Stop all types of future commercial email from National Geographic regarding its products, services, or experiences.

Manage all email preferences with the Walt Disney Family of Companies.

© 2022 National Geographic Partners, LLC, All rights reserved.